

6 April 2020

ASX ANNOUNCEMENT

US FDA clearance for ADAPT[®] tissue

Admedus Limited (ASX:AHZ) (**Admedus** or the **Company**) announces US FDA clearance of an indication change to its ADAPT[®]-treated (bovine pericardium) tissue through the Special 510(k) pathway.

The change extends ADAPT[®] tissue approval for use in cardiac defects, including intracardiac defects, septal defects and valve and annulus repairs.

“This approval marks an important distinction from previous approvals and clears the way for future approvals of ADAPT based material for our aortic valve products” commented Wayne Paterson CEO.

ENDS

About Admedus Limited (ASX: AHZ)

Admedus Ltd is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Ms Kyahn Williamson
WE Communications
E: WE-AUAdmedus@we-worldwide.com
P: +61 401 018 828

www.admedus.com

Twitter: @Admedus

Facebook: www.facebook.com/admedus/

Admedus Limited

Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: info@admedus.com W: admedus.com

